Comprehensive mass spectrometry based biomarker discovery and validation platform as applied to diabetic kidney disease

Abstract

HighlightsA direct proteomics-based biomarker discovery to validation workflow is proposed.Targeted mass spectrometry enabled robust multiplexing assays.The mass spectrometry assay demonstrated CV's of: intra-day 5.9% and inter-day 8.1%.A protein biomarker panel has been developed specific for diabetic kidney disease.The biomarker panel presented outperforms current gold standard tests.

Identification of Novel Circulating Biomarkers Predicting Rapid Decline in Renal Function in Type 2 Diabetes: The Fremantle Diabetes Study Phase II

“…The present substudy from the longitudinal observational FDS2 has extended preliminary developmental data relating to a novel panel of plasma proteins (PromarkerD) (19) to confirm that these biomarkers have prognostic use in DKD. Four biomarkers, apoA4, CD5L, C1QB, and IBP3, predicted measures of rapid decline in eGFR over a 4-year follow-up period in community-based patients with type 2 diabetes.…”

“…Biomarker discovery has been described previously (19). In brief, a list of candidate biomarkers was determined by a proteomics mass spectrometry-based discovery and validation workflow.…”

The role of mass spectrometry in studies of glycation processes and diabetes management

“…() performed a longitudinal observational study to assess the ability of six novel circulating biomarkers to predict rapid declining of the estimated GFR (eGFR) in subjects with type 2 diabetes. The six biomarkers selected belong to a novel panel of plasma proteins identified in a preliminary studied, focused on the discovery, and the sequent validation, of biomarkers for DKD by the use of MS (Bringans et al ., ). Totally, 345 T2DM patients were studied and divided in rapid and non‐rapid decliners depending on eGFR change over the 4 years of follow up.…”

An integrative systems biology approach for precision medicine in diabetic kidney disease

“…High‐throughput multi‐omics approaches (transcriptomics, proteomics, metabolomics and lipidomics) have been used to profile patients' biospecimen (kidney biopsy, plasma and urine samples). These multi‐omics data sets contributed to the discovery of biomarker candidates that are associated with disease progression . Table includes molecular biomarkers that were discovered using systems biology approaches with demonstrated association with kidney outcomes in patient‐related studies.…”

“…These multiomics data sets contributed to the discovery of biomarker candidates that are associated with disease progression. 17,[22][23][24][25][26][27][28][29] Table 2 includes molecular biomarkers that were discovered using systems biology approaches with demonstrated association with kidney outcomes in patient-related studies.…”